BAY-43-9006 Bayer/Onyx

Current Opinion in Investigational Drugs

Volumn 4, Issue 6, 2003, Pages 757-763

  Lee, John T ^a   McCubrey, James A ^a  

^a EAST CAROLINA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; GEMCITABINE; GW 374; IMATINIB; IRINOTECAN; L 779450; N (4 CHLORO 3 TRIFLUOROMETHYLPHENYL) N' [4 [2 (N METHYLCARBAMOYL) 4 PYRIDYLOXY]PHENYL]UREA; NAVELBINE; PACLITAXEL; PROTEIN INHIBITOR; SORAFENIB; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADD ON THERAPY; ANEMIA; ANOREXIA; CANCER; CLINICAL TRIAL; DIARRHEA; DISEASE SEVERITY; DOSE CALCULATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOXICITY; FATIGUE; FLATULENCE; HUMAN; INHIBITION KINETICS; MONOTHERAPY; NAUSEA; NEUTROPENIA; NONHUMAN; PHARMACOLOGICAL PARAMETERS; PRURITUS; REVIEW; SKIN TOXICITY; STRUCTURE ACTIVITY RELATION; THROMBOCYTOPENIA; VOMITING;

ANIMALS; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CLINICAL TRIALS; DRUGS, INVESTIGATIONAL; HUMANS; NEOPLASMS; PYRIDINES; TECHNOLOGY, PHARMACEUTICAL;

EID: 0042666798     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (46)

1. 285016 Identification of potent, selective kinase inhibitors of Raf. Heimbrook DC, Huber HE, Stirdivant SM, Claremon D, Liverton N, Patrick DR, Selnick H, Ahern J, Conroy R, Drakas R, Falconi N et al Proc Annu Meet Am Assoc Cancer Res 1998 39 Abs 3793
2. 322585 Drug discovery efforts toward the identification of c-Raf1 kinase inhibitors as anti-cancer agents. Lackey K, Chapman D, Crosby RM, Davenport E, Dickerson S, Gilmer TM, Griffin RJ, Hunter RN, Jung DK, Keith BR, Mahoney WB et al Proc Annu Meet Am Assoc Cancer Res 1999 40 Abs 828
3. 322280 American Association for Cancer Research - 90th Annual Meeting (Part XII), Philadelphia, PA, USA. Kelland LR IDDB Meeting Report 1999 April 10-14
4. 337456 Screen '99 San Diego, CA, USA. IDDB Meeting Report 1999 August 9-13
5. 390882 Discovery of a novel class of potent Raf kinase inhibitors: Structure activity relationships. Lowinger T, Riedl B, Wood J, Dumas J, Smith RA, Khire U, Bankston D, Monahan MK, Scott WJ, Lee W, Johnson JS et al NCI EORTC Symp New Drugs Cancer Ther 2000 11 November 7-11 Abs 335
6. 402451 Potent Raf kinase inhibitors from the diphenylurea class: Structure activity relationships. Riedl B, Lowinger TB, Bankston D, Barbosa J, Brittelli D R, Carlson R, Dumas J, Hibner B, Kadano H, Katz M, Kennure N et al Proc Annu Meet Am Assoc Cancer Res 2001 42 March 24-28 Abs 4956
7. 403615 American Association for Cancer Research 92nd Annual Meeting (Part VII), New Orleans, LA, USA. Jones E IDDB Meeting Report 2001 March 24-28
8. 404504 Phase I and pharmacokinetic study of the rat kinase inhibitor BAY 43-9006 in patients with locally advanced or metastatic cancer. Strumberg D, Schuehly U, Moeller JG, Hedley D, Hilger R, Stellberg W, Richly H, Heinig R, Kuhlmann J, Scheulen ME, Seeber S Proc Annu Meet Am Assoc Cancer Res 2001 42 Abs 2921
9. 404875 American Association for Cancer Research 92nd Annual Meeting (Part XI), Novel Molecular Targets and Drugs New Orleans, LA, USA. Clarke R IDDB Meeting Report 2001 March 24-28
10. 408527 Drug development pipeline: BAY-43-9006, Raf inhibitors, ONYX/Bayer. Bayer Corp Company Communication 2001 May 08
11. 409891 Phase I clinical, pharmacokinetic and pharmacodynamic study of the Raf kinase inhibitor BAY 43-9006 in patients with locally advanced or metastatic cancer. Strumberg D, Schuehly U, Moeller J G, Hedley D, Hilger R, Stellberg W, Richly H, Heinig R, Ahr G, Wensing G, Kuhlmann J et al Proc Am Soc Clin Oncol 2001 20 Pt 1 Abs 330
12. 425815 Discovery of heteroocyclic ureas as a new class of raf kinase inhibitors: Identification of a second generation lead by a combinatorial chemistry approach. Smith RA, Barbosa J, Blum C, Bobko MA, Caringl YV, Dally R, Johnson J, Katz ME, Kennure N, Kingrey Wood J, Lee W et al Bioorg Med Chem Lett 2001 11 20 2775-2778 An original publication describing the synthesis of heterocyclic ureas as novel Raf kinase inhibitors.
13. 427755 BAY 43-9006 phase I data presented at 2001 AACR-NCI-EORTC meeting. Onyx Pharmaceuticals Inc, Bayer Corp Press Release 2001 November 01
14. 430134 A phase I pharmacokinetic and pharmacodynamic study of the Raf kinase inhibitor BAY 43-9006 given orally to patients with solid tumors. Strumberg D, Bauer RJ, Moeller JG, Hilger R, Diaz-Carballo D, Richly H, Kredtke S, Beling C, Faghih M, Heinig R, Hedley D et al AACR NCI EORTC Mol Targets Cancer Ther 2001 October 29-November 02 Abs 285
15. 430159 Application of a novel flow cytometry method for pharmacodynamic monitoring of the Raf kinase inhibitor BAY 43-9006 during phase I clinical trial. Hedley DW, Chow S, Moore MJ, Bollag G, Lyons J, Wilhelm S AACR NCI EORTC MOL Targets Cancer Ther 2001 October 29-November 02 Abs 293
16. 436956 Phase I study to determine the safety and pharmacokinetics of BAY 43-9006 in patients with advanced refractory solid tumors. Hirte H, Moore MJ, Oza AM, Siu LL, Harris H, Maclean M, Petreniuc O, Fiander W, Lathia C AACR NCI EORTC Mol Targets Cancer Ther 2001 October 29-November 02 Abs 567
17. 436952 A clinical, pharmacokinetic and pharmacodynamic phase I study of the Raf kinase inhibitor BAY 43-9006 in patients with advanced solid cancers. Awada A, Hendlisz A, Gil T, Bleiberg H, Bartholomeus S, De Valeriola D, Dewitte M, Coppieters S, Moeller J, De Becker D, Meert A et al AACR NCI EORTC Mol Targets Cancer Ther 2001 October 29-November 02 Abs 569
18. 451786 Final results of a phase I pharmacokinetic and pharmacodynamic study of the Raf kinase inhibitor BAY 43-9006 in patients with solid tumors. Strumberg D, Bauer RJ, Moeller JG, Hilger RA, Richly H, Kredtke S, Beling C, Faghih M, Heinig R, Hedley D, Scheulen ME, Seebers S Proc Am Soc Clin Oncol 2002 21 1 Abs 121
19. 451999 New BAY 43-9006 phase I data presented at 2002 ASCO meeting. Onyx Pharmaceuticals Inc Press Release 2002 May 21
20. 452880 Phase 1 study of the Raf-1 kinase inhibitor Bay 43-9006 in patients with advanced refractory solid tumors. Moore M, Maclean M, Petenciuc O, Fiander W, Lathia C Proc Am Soc Clin Oncol 2002 21 1 Abs 1816
21. 453077 Chemotherapy with the Raf kinase inhibitor BAY 43-9006 in combination with irinotecan, vinorelbine, or gemcitabine is well tolerated and efficacious in preclinical xenografts models. Vincent P, Zhang X, Chen C, Lantz L, Rembiessa C, Polony B, Carter CA Proc Am Soc Clin Oncol 2002 21 2 Abs 1900
22. 453133 Inhibition of ERK phosphorylation and clinical outcome in patients treated with the Raf kinase inhibitor BAY 43-9006. Moeller JG, Bauer RJ, Stellberg W, Seeber S, Scheulen ME, Strumberg D Prof Am Soc Clin Oncol 2002 21 1 Abs 1916
23. 456813 Discovery of a novel Raf kinase inhibitor. Lyons JF, Wilhelm S, Hibner B, Bollag G Endocr-Relat Cancer 2001 8 219-225 A peer-reviewed, introductory review that discusses the need for Raf inhibitors as well as early studies with BAY-43-9006.
24. 463092 Onyx and Bayer initiate phase II studies of Raf kinase inhibitor. Onyx Pharmaceuticals Inc Press Release 2002 September 04
25. 463753 Ω-Carboxypyridyl substituted ureas as Raf kinase inhibitors. Khire U, Dumas J, Riedl B, Smith R, Lowinger T, Wood J, Brittelli D Proc Annu Meet Am Assoc Cancer Res 2002 43 Abs 4211
26. 463765 Inhibition of ERK phosphorylation in patients treated with the Raf kinase inhibitor BAY 43-9006. Hilger RA, Kredtke S, Hedley D, Moeller JG, Bauer RJ, Stellberg W, Seeber S, Scheulen ME, Strumberg D Proc Annu Meet Am Assoc Cancer Res 2002 43 Abs 2973
27. 463772 A novel diphenylurea Raf-1 kinase inhibitor (RKI) blocks the Raf/Mek/Erk pathway in tumor cells. Wilhelm SM, Housley T, Kennure N, Rong H, Carlson R, Hibner B, Riedl B, Lyons J, Taylor R, Bollag G, Roscoe W Proc Annu Meet Am Assoc Cancer Res 2001 42 4957
28. 463774 Anti-tumor efficacy of the orally active Raf kinase inhibitor BAY 43-9006 in human tumor xenograft models. Carter CA, Gianpaolo Ostravage C, Hibner B, Bankston D, Natero R, Monahan MK, Riedl B Proc Annu Meet Am Assoc Cancer Res 2001 42 Abs 4954
29. 466338 The Raf/MEK/ERK signal transduction cascade as a target for chemotherapeutic intervention in leukaemia. Lee JT, McCubrey JA Leukemia 2002 16 4 486-507
30. 466340 Targeting the Raf kinase cascade in cancer therapy: Novel molecular, targets and therapeutic strategies. Lee JT, McCubrey JA Exp Opin Ther Targets 2003 in press
31. 466916 New drugs in the R&D pipeline. Pharma Jpn 2002 1815 October 14 9
32. 470312 Onyx provides update of development programs; Meets key manufacturing milestone. Onyx Pharmaceuticals Inc Press Release 2002 November 14
33. 470750 Final results of a clinical and pharmacokinetic (PK) phase I study of the Raf kinase inhibitor BAY 43-9006 in refractory solid cancers: A promising antitumor agent. Awada A, Hendlisz A, Gil T, Munoz R, Bartholomeus S, De Valeriola D, Van Der Auwera J, Coppieters S, Moeller JG, Piccart M. AACR NCI EORTC Mol Targets Cancer Ther 2002 November 19-22 Abs 162
34. 471717 BAY 43-9006: Early clinical data in patients with advanced solid malignancies. Hotte SJ, Hirte HW Curr Pharm Design 2002 8 25 2249-2253 This article encompasses much of the available phase I trial data in relative detail.
35. 471718 BAY 43-9006: Preclinical data. Wilheim S, Chien DS Curr Pharm Design 2002 8 25 2255-2257 Succinct review, co-written by developers of the drug, covering data from a number of important abstracts.
36. 471721 Design and discovery of small molecules targeting Raf-1 kinase. Lowinger TB, Riedl B, Dumas J, Smith RA Curr Pharm Design 2002 8 25 2269-2278 Comprehensive review covering the complete synthesis and SAR of BAY-43-9006.
37. 471765 BAY-43-9006, a Raf inhibitor with a novel mechanism of action. Lyons JF, Hibner B, Gianpaolo-Ostravage C, Bankston D, Natero R, Chien DS, Dumas J, Riedl B, Roscoe W, Housley T, Kennure N et al Proc Natl Acad Sci USA 2003 in press
38. 473339 Imatinib-resistant cell lines are sensitive to the Raf inhibitor BAY 43-9006. Choi Y-JC, Wang Q, White S, Gorre M, Sawyers CL, Bollag G. Blood 2002 100 11 Abs 1427
39. 475714 Perspectives: Pipeline pulse: 1,000+ drugs in development provide bright future for industry. Scala SM, Sanderson IC, Moran JR, Cacciatore KC, Perreault JB SG Cowen Securities Corporation 2002 October
40. 479169 New targets and innovative strategies in cancer treatment. A short course for clinicians, Monte Carlo, Monaco. Eskens F IDDB Meeting Report 2003 February 07-08
41. 492982 Final results of a phase I study to determine the safety, maximum tolerated dose, pharmacokinetics and pharmacodynamics of BAY 43-9006 in repeated cycles of 1 week on / 1 week off in patients with advanced, refractory solid tumors. Wong KK, Eder JP, Clark J, Lenz HJ, Smith J, Lee RJ, Lathia C, Humphrey R Proc Am Soc Clin Oncol 2003 22 Abs 976
42. 491537 Final report of the phase I clinical program of the novel Raf kinase inhibitor BAY 43-9006 in patients with refractory solid tumors. Strumberg D, Awada A, Piccart M, Hirte H, Moore M, Clark J, Lenz HJ, Lathia C, Coppieters S, Humphrey R Proc Am Soc Clin Oncol 2003 22 Abs 813
43. 491853 Novel Raf kinase inhibitor BAY 43-9006 shows early signs of tolerability and activity in phase Ib combination trials reported at ASCO. Bayer Pharmaceuticals Corp, Onyx Pharmaceuticals Inc Press Release 2003 June 02
44. 492037 Phase I trial of BAY 43-9006 in combination with carboplatin (C) and paclitaxel (P). Flaherty KT, Lee RJ, Humphries R, O'Dwyer PJ, Schiller J Proc Am Soc Clin Oncol 2003 22 Abs 2854
45. 493380 American Society of Clinical Oncology - 39th Annual Meeting (Part IX), Chicago, IL, USA. Susman E IDDB Meeting Report 2003 May 31-June 03
46. 491883 Phase I study of oral Raf-1 kinase inhibitor BAY 43-9006 with gemcitabine in patients with advanced solid tumors. Siu L, Awada A, Takimoto CH, Moore MJ, Piccart M, Fiander W, Lathia C, Petrenciuc O Proc Am Soc Clin Oncol 2003 22 Abs 828